Tilray | TRLY - Ebit


Tilray reported $-20.01M in EBIT for its fiscal quarter ending in September of 2025.





Ebit Change Date
Acasti Pharma USD -3.7M 1.13M Dec/2024
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alaunos Therapeutics USD -1.01M 175K Mar/2026
Aurora Cannabis CAD -35.79M 8.96M Dec/2025
Avita Medical AUD -10.39M 1.72M Dec/2025
Canopy Growth CAD -12.66M 1.64M Dec/2025
Cronos Group USD -1.45M 5.61M Mar/2026
Dianthus Therapeutics USD -69.54M 29.25M Dec/2025
Divis Laboratories Ltd INR 8.14B 420M Mar/2026
Ionis Pharmaceuticals USD -118M 97M Mar/2026
IQVIA Holdings USD 565M 2.11B Mar/2026
Knight Therapeutics CAD 6.21M 3.27M Dec/2025
Moderna USD -1.39B 531M Mar/2026
Organigram Holdings CAD -20.13M 7.92M Dec/2025
Organon & Co USD -27M 415M Dec/2025
Revvity USD 82.77M 63.06M Mar/2026
Tectonic Therapeutic USD -21.52M 374K Dec/2025
Tilray USD -20.01M 9.34M Sep/2025
Viatris USD -20.2M 137.3M Mar/2026
Xeris Pharmaceuticals USD 16.77M 8.88M Dec/2025
Zealand Pharma A/S -707.05M 245.73M Dec/2025